TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of probable Major Depressive Disorder (MDD)
Endpoint domain: Mortality/survival
Primary endpoint: Consonant proficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with no HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diagnostic delay of hypophosphatasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Participant Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Related Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change on analgesic needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity and specificity of breast cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Radiographic incidence rate of incisional hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Older People's Quality of Life Questionnaire (OPQOL-brief)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: fatigue severity assessment scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Morphology of the platelet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of granules in the platelet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of mitochondria, glycogen and dense tubular system in platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interactions between parents and child
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Efficacy of LNZ101/LNZ100 in treating Presbyopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day 29 GMT ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Day 29 GMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Day 1 to Day 29 SCR and SCR difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Cardiovascular Death
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of Non-fatal Myocardial Infarction (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Non-fatal Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nursing Diagnosis Perception Scale (NDPS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Therapeutic Communication Skills Scale for Nursing Students (TCSSNS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bilateral BIS values (derived from EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propofol cumulative dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Adverse Events of Interest (EOI)
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiovascular marker of stressor intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence and severity of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fracture related infection (FRI) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic performance of 64Cu-SAR-bisPSMA PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in S. mutans counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of steatohepatitis and no worsening of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Improvement in liver fibrosis and no worsening of steatohepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Cirrhosis-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean Photopic Monocular Best Corrected Distance Visual Acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Adverse Events, including Secondary Surgical Interventions (SSIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in children's emotional symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response to anti-VZV therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of months in remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frankel scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Karnofsky score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: urinary sphincter control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: performance and quality of life (EQ5D_3L) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in composition of the microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the immune cell environment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete or partial remission of nephrotic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in the level of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in the level of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in the level of stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite of Major Renal Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of patients with improvement in symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical Activity Levels measure with IPAQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dyspnoea measure with Borg Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of leadership competency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ability to use leadership competency
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Leadership effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Saturation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relationship between tidal volume set and observed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Time to Complete the Instrumented Timed Up and Go Test (iTUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Duration of Balance During Romberg Test Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Primary Prostate Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: TMA occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of progression
Endpoint domain: Adverse events/effects
Primary endpoint: Probability of developing acute GVHD stage II-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severe (3-5 degrees) side effects of conditioning
Endpoint domain: Adverse events/effects
Primary endpoint: Quick Disability of Arm, Shoulder, Hand (QuickDASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain by Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new community acquired pressure injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in FGV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Findings of isokinetic dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fold change of anti-gE antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative ocular surface disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Patient Health Questionnaire-9 Items (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Who Achieved Confirmed Clearance of Plasma CMV Deoxyribose Nucleic Acid (DNA) at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With TEAEs Leading to Treatment Discontinuation With Maribavir
Endpoint domain: Adverse events/effects
Primary endpoint: Verified PrEP Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concentration of serum zonisamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline visual analog scale (VAS) wrist pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in a structured interview
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of participants with an AE / ADR
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with a SAE / SADR
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with an UAE/ UADR
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with a SUAE/ SUADR
Endpoint domain: Adverse events/effects
Primary endpoint: Change in completion of advance directives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EURO QoL 5D 5L quality-of-life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual acuity (final point)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The McGill Pain Questionnaire (final)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional Independence Measure (FIM) questionnaire (final)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Generic SF-12 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Specific QLQ-C30 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MSOT parameters of the gastrocnemius muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of spontaneous complete bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Numerical Pain Rating Scale (NPRS) Anterior Knee Pain changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The OKS (Oxford Knee Score) questionnaire for knee function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival at 7 months (OS7)
Endpoint domain: Mortality/survival
Primary endpoint: Change in probing depths (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard uptake value ratio (SUVR) targeting brain tau deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Obstructive Ventilatory Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of Anti-HER2 Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in consciousness 12 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of New COVID-19 Detected Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Knees Achieving Post-Operative Leg Alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturnal respiratory exchange ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in motor performance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lordatic angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of clinical seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Summarized volume of TSC-associated tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of HSV-1 Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average duration of absolute neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change scores of Wechsler Memory Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Device-related seroma or infection
Endpoint domain: Adverse events/effects
Primary endpoint: Secondary patency (revascularization)
Endpoint domain: Physiological/clinical
Primary endpoint: Survival through 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Primary patency through 5 years
Endpoint domain: Physiological/clinical
Primary endpoint: Device-related infection through 2 years
Endpoint domain: Adverse events/effects
Primary endpoint: Useable access circuit (reported as secondary patency) through 2 years
Endpoint domain: Physiological/clinical
Primary endpoint: Microvascular blood flow volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in periodontitis status after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent clinically significant laboratory test results
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent clinically significant electrocardiograms (ECGs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent clinically abnormal vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of encounters with an opioid transitioning prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in FMA from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NIHSS from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WMFT from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in JTT from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NHP from baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual Function Battery for Children with Special Needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Vision Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eye Movement Assessment Behavioral Scale for Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Detection Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ctDNA Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ctDNA Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ctDNA Progression of Disease (POD) or Clinical/radiographic Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes from baseline in the mean literacy and numeracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes from baseline in the mean knowledge and awareness risks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes from baseline in the mean skills and self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes from baseline in the mean environmental health engagement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Absence of primary irritability potential
Endpoint domain: Adverse events/effects
Primary endpoint: Mean WASO (wakefulness after sleep onset)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menopause-specific quality-of-life questionnaire (MENQOL) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Insomnia Severity Index (ISI) total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficiency of the PRPP system for living orientation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in percent Body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glucose effectiveness (Sg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: psychological well-being scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Volumetric bone volume healing assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: pelvic floor muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antero posterior stability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medio lateral stability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stability and sway indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to block of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to block of thermosensory perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Return to Duty
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Graft failure/rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported Cigarette Smoking Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Vaping/ENDS Risk of Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Smokeless Tobacco Use Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Cigarillo/Little Cigar Use Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Pure Tone Average from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Word recognition score from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of vaccine studies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of new ways of delivering research
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with Ventilator-Associated Events
Endpoint domain: Adverse events/effects
Primary endpoint: arterial level of lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diastolic Dysfunction Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Who Receive TPT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participants with Positive TB test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time (days) to TB treatment initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intraoperative haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 1-year Progression-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Measurable residual disease (MRD) negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participants Who Have Achieved Smoking cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: National Institute of Health stroke scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Major ischemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Successful rate of breast-conserving surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Measure of the outer framework of the nose after trauma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to lipid attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipid attainment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline in physical examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes